<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zabmedvestnik</journal-id><journal-title-group><journal-title xml:lang="ru">Забайкальский медицинский вестник</journal-title><trans-title-group xml:lang="en"><trans-title>Transbaikalian Medical Bulletin</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">1998-6173</issn><publisher><publisher-name>Читинская государственная медицинская академия</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52485/19986173_2023_2_173</article-id><article-id custom-type="elpub" pub-id-type="custom">zabmedvestnik-181</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>НАУЧНЫЕ ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>SCIENTIFIC REVIEWS</subject></subj-group></article-categories><title-group><article-title>МЕТАБОЛИТЫ КИНУРЕНИНОВОГО ПУТИ ОБМЕНА ТРИПТОФАНА   В РАЗВИТИИ АНГИОПАТИЙ ПРИ САХАРНОМ ДИАБЕТЕ</article-title><trans-title-group xml:lang="en"><trans-title>KYNURENINE PATHWAY METABOLITES OF TRYPTOPHAN METABOLISM IN  THE DEVELOPMENT OF ANGIOPATHIES DURING DIABETES MELLITUS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фефелова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fefelova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Чита, ул. Горького, 39а, 672000</p></bio><bio xml:lang="en"><p>Chita, Gorky str., 39A, 672000 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Саклакова</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Saklakova</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> г. Чита, ул. Коханского, 7, 672038</p></bio><bio xml:lang="en"><p>Chita, Kokhansky Street, 7672038 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максименя</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimenya</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Чита, ул. Горького, 39а, 672000</p></bio><bio xml:lang="en"><p>Chita, Gorky str., 39A, 672000 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Коцюржинская</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Kotsyurzhinskaya</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Чита, ул. Горького, 39а, 672000</p></bio><bio xml:lang="en"><p>Chita, Gorky str., 39A, 672000 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Караваева</surname><given-names>Т. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Karavaeva</surname><given-names>T. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Чита, ул. Горького, 39а, 672000</p></bio><bio xml:lang="en"><p>Chita, Gorky str., 39A, 672000 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Терешков</surname><given-names>П. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Tereshkov</surname><given-names>P. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>г. Чита, ул. Горького, 39а, 672000</p></bio><bio xml:lang="en"><p>Chita, Gorky str., 39A, 672000 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Читинская государственная медицинская академия» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chita State Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Государственное учреждение здравоохранения «Краевая клиническая больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Public Health Agency “Regional Clinical Hospital”</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>05</day><month>08</month><year>2024</year></pub-date><volume>0</volume><issue>2</issue><fpage>173</fpage><lpage>189</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фефелова Е.В., Саклакова О.А., Максименя М.В., Коцюржинская Н.Н., Караваева Т.М., Терешков П.П., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Фефелова Е.В., Саклакова О.А., Максименя М.В., Коцюржинская Н.Н., Караваева Т.М., Терешков П.П.</copyright-holder><copyright-holder xml:lang="en">Fefelova E.V., Saklakova O.A., Maksimenya M.V., Kotsyurzhinskaya N.N., Karavaeva T.M., Tereshkov P.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.zabmedvestnik.ru/jour/article/view/181">https://www.zabmedvestnik.ru/jour/article/view/181</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Обзор современных сведений об участии промежуточных продуктов кинуренинового пути в патогенезе осложнений СД, а именно ангиопатий. </p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Выполнен электронный поиск научной литературы в PubMed и Embase, опубликованной до марта 2023 года на предмет статей, в которых сообщалось об особенностях обмена триптофана (TRP), кинуренина (KYN), кинуреновой кислоты (KYNA), ксантуреновой кислоты (XA), антраниловой кислоты (AA) и хинолиновой кислоты (QA) в норме и при сахарном диабете (СД), особое внимание уделялось роли кинуренинов в развитии дисфункции эндотелия. </p></sec><sec><title>Результаты</title><p>Результаты. Описано влияние многих кинуренинов на углеводный обмен, свободнорадикальные процессы, иммунные реакции, раскрыта их роль в формировании некоторых патологий, в том числе таких, как метаболический синдром, сахарный диабет и его сосудистые осложнения. </p></sec><sec><title>Заключение</title><p>Заключение. Кинурениновый путь преобразования TRP выполняет несколько важных функций в организме, результаты исследований звеньев его течения постепенно выявляют сложные взаимоотношения между метаболическими нарушениями обмена триптофана, сахарным диабетом и сосудистыми осложнениями. Многие вопросы остаются неизученными, в представленном обзоре литературы намечены некоторые патогенетические взаимосвязи. </p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To review current data about the participation of kynurenine pathway’s intermediate products in the pathogenesis of complications of diabetes, namely angiopathy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. There was an electronic research of the scientific literature in PubMed and Embase published up to March 2023 for articles that reported on the features of the metabolism of tryptophan (TRP), kynurenine (KYN), kynurenic acid (KYNA), xanthurenic acid (XA), anthranilic acid (AA) and QUINoline acid (QA) in normal state and during diabetes mellitus (DM). Special attention was paid to the role of kynurenines in the development of endothelial dysfunction.</p></sec><sec><title>Results</title><p>Results. A descriptive research of the variety of kynurenines’ influence on carbohydrate metabolism, free radical processes, immune responses is described, as well as their role in the formation of some pathologies, including metabolic syndrome, diabetes mellitus and its vascular complications, is presented.</p></sec><sec><title>Conclusion</title><p>Conclusion. The kynurenine pathway of TRP conversion performs several important functions in the body; the results of studies of its course features gradually reveal the complicated relationship between metabolic disorders of tryptophan metabolism, diabetes mellitus and vascular complications. Many issues remain unexplored; some pathogenetic relationships are outlined in currnet literature review.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>триптофан</kwd><kwd>кинурениновый путь</kwd><kwd>сахарный диабет</kwd><kwd>ангиопатии</kwd></kwd-group><kwd-group xml:lang="en"><kwd>tryptophan</kwd><kwd>kynurenine pathway</kwd><kwd>diabetes mellitus</kwd><kwd>angiopathy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Badawy A.A. Kynurenine pathway and human systems. Exp. Gerontol. 2020. 129. 110770.DOI10.1016/j.exger.2019.110770.</mixed-citation><mixed-citation xml:lang="en">Badawy A.A. Kynurenine pathway and human systems. Exp. Gerontol. 2020. 129. 110770.DOI10.1016/j.exger.2019.110770.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Sas K., Szabo E., Vecsei L. Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection. Molecules. 2018. 23. 19. DOI10.3390/molecules23010191.</mixed-citation><mixed-citation xml:lang="en">Sas K., Szabo E., Vecsei L. Mitochondria, Oxidative Stress and the Kynurenine System, with a Focus on Ageing and Neuroprotection. Molecules. 2018. 23. 19. DOI10.3390/molecules23010191.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kiluk M., Lewkowicz J., Pawlak D., Tankiewicz-Kwedlo A. Crosstalk between Tryptophan Metabolism via Kynurenine Pathway and Carbohydrate Metabolism in the Context of CardioMetabolic Risk-Review. J Clin Med. 2021. 10(11). 2484. DOI 10.3390/jcm10112484.</mixed-citation><mixed-citation xml:lang="en">Kiluk M., Lewkowicz J., Pawlak D., Tankiewicz-Kwedlo A. Crosstalk between Tryptophan Metabolism via Kynurenine Pathway and Carbohydrate Metabolism in the Context of CardioMetabolic Risk-Review. J Clin Med. 2021. 10(11). 2484. DOI 10.3390/jcm10112484.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Kozieł K., Urbanska E.M. Kynurenine Pathway in Diabetes Mellitus-Novel Pharmacological Target? Cells. 2023. 12(3). 460. DOI 10.3390/cells12030460.</mixed-citation><mixed-citation xml:lang="en">Kozieł K., Urbanska E.M. Kynurenine Pathway in Diabetes Mellitus-Novel Pharmacological Target? Cells. 2023. 12(3). 460. DOI 10.3390/cells12030460.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gáspár R., Halmi D., Demján V. et al. Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease. Front Immunol. 2022. 12. 768560. DOI 10.3389/fimmu.2021.768560.</mixed-citation><mixed-citation xml:lang="en">Gáspár R., Halmi D., Demján V. et al. Kynurenine Pathway Metabolites as Potential Clinical Biomarkers in Coronary Artery Disease. Front Immunol. 2022. 12. 768560. DOI 10.3389/fimmu.2021.768560.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J.J., Movassat J., Portha B. Emerging role for kynurenines in metabolic pathologies. Curr.Opin. Clin. Nutr. Metab. Care. 2019. 22. 82-90. DOI10.1097/MCO.0000000000000529.</mixed-citation><mixed-citation xml:lang="en">Liu J.J., Movassat J., Portha B. Emerging role for kynurenines in metabolic pathologies. Curr.Opin. Clin. Nutr. Metab. Care. 2019. 22. 82-90. DOI10.1097/MCO.0000000000000529.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ala M., Eftekhar S.P. The Footprint of Kynurenine Pathway in Cardiovascular Diseases. Int J Tryptophan Res. 2022. 15. 11786469221096643. DOI 10.1177/11786469221096643.</mixed-citation><mixed-citation xml:lang="en">Ala M., Eftekhar S.P. The Footprint of Kynurenine Pathway in Cardiovascular Diseases. Int J Tryptophan Res. 2022. 15. 11786469221096643. DOI 10.1177/11786469221096643.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Moffett J.R., Arun P., Puthillathu N. et al. QUINolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD+ Synthesis During Inflammation and Infection. Front Immunol. 2020. 11. 31. DOI 10.3389/fimmu.2020.00031.</mixed-citation><mixed-citation xml:lang="en">Moffett J.R., Arun P., Puthillathu N. et al. QUINolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD+ Synthesis During Inflammation and Infection. Front Immunol. 2020. 11. 31. DOI 10.3389/fimmu.2020.00031.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 1 типа у взрослых. Сахарный диабет. 2020. 23(1S). 42-114. DOI 10.14341/DM12505.</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Шестакова М.В., Майоров А.Ю. и др. Сахарный диабет 1 типа у взрослых. Сахарный диабет. 2020. 23(1S). 42-114. DOI 10.14341/DM12505.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sorgdrager F.J.H., Naudé P.J.W., Kema I.P. et al. Tryptophan Metabolism in Inflammaging: From Biomarker to Therapeutic Target. Front. Immunol. 2019. 10. DOI10.3389/fimmu.2019.02565.</mixed-citation><mixed-citation xml:lang="en">Sorgdrager F.J.H., Naudé P.J.W., Kema I.P. et al. Tryptophan Metabolism in Inflammaging: From Biomarker to Therapeutic Target. Front. Immunol. 2019. 10. DOI10.3389/fimmu.2019.02565.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ramprasath T., Han Y.M., Zhang D. et al. Tryptophan Catabolism and Inflammation: A Novel Therapeutic Target For Aortic Diseases. Front Immunol. 2021. 12. 731701. DOI 10.3389/fimmu.2021.731701.</mixed-citation><mixed-citation xml:lang="en">Ramprasath T., Han Y.M., Zhang D. et al. Tryptophan Catabolism and Inflammation: A Novel Therapeutic Target For Aortic Diseases. Front Immunol. 2021. 12. 731701. DOI 10.3389/fimmu.2021.731701.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Anquetil F., Mondanelli G., Gonzalez N. et al. Loss of IDO1 Expression From Human Pancreatic β-Cells Precedes Their Destruction During the Development of Type 1 Diabetes. Diabetes. 2018. 67. 1858-1866. DOI10.2337/db17-1281.</mixed-citation><mixed-citation xml:lang="en">Anquetil F., Mondanelli G., Gonzalez N. et al. Loss of IDO1 Expression From Human Pancreatic β-Cells Precedes Their Destruction During the Development of Type 1 Diabetes. Diabetes. 2018. 67. 1858-1866. DOI10.2337/db17-1281.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hughes T.D., Güner O.F., Iradukunda E.C. et al. The Kynurenine Pathway and Kynurenine 3Monooxygenase Inhibitors. Molecules. 2022. 27(1). 273. DOI 10.3390/molecules27010273.</mixed-citation><mixed-citation xml:lang="en">Hughes T.D., Güner O.F., Iradukunda E.C. et al. The Kynurenine Pathway and Kynurenine 3Monooxygenase Inhibitors. Molecules. 2022. 27(1). 273. DOI 10.3390/molecules27010273.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Мейрамов Г.Г., Конерт К.Д., Мейрамова А.Г. О диабетогенном действии ксантуреновой кислоты. Проблемы Эндокринологии. 2001. 47(1). 39-44. DOI 10.14341/probl11316.</mixed-citation><mixed-citation xml:lang="en">Meyramov G.G., Konert K.D., Meyramova A.G. On the diabetogenic action of xanthurenic acid. Problemy Endokrinologii. 2001. 47(1). 39-44. DOI 10.14341/probl11316. in Russian.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Thirtamara-Rajamani K., Li P., Escobar Galvis M.L. et al. Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson's Disease? J Parkinsons Dis. 2017. 7(4). 577-587. DOI 10.3233/JPD-171240.</mixed-citation><mixed-citation xml:lang="en">Thirtamara-Rajamani K., Li P., Escobar Galvis M.L. et al. Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson's Disease? J Parkinsons Dis. 2017. 7(4). 577-587. DOI 10.3233/JPD-171240.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Pelcl T., Skrha J., Prazny M. et al. Diabetes, Cardiovascular Disorders and 2,3,7,8Tetrachlorodibenzo-p-Dioxin Body Burden in Czech Patients 50 Years After the Intoxication. Basic Clin. Pharmacol. Toxicol. 2018. 123. 356-359. DOI10.1111/bcpt.13013.</mixed-citation><mixed-citation xml:lang="en">Pelcl T., Skrha J., Prazny M. et al. Diabetes, Cardiovascular Disorders and 2,3,7,8Tetrachlorodibenzo-p-Dioxin Body Burden in Czech Patients 50 Years After the Intoxication. Basic Clin. Pharmacol. Toxicol. 2018. 123. 356-359. DOI10.1111/bcpt.13013.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tanabe A., Egashira Y., Fukuoka S. et al. Expression of rat hepatic 2-amino-3-carboxymuconate6-semialdehyde decarboxylase is affected by a high protein diet and by streptozotocin-induced diabetes. J Nutr. 2002. 132(6). 1153-9. DOI 10.1093/jn/132.6.1153.</mixed-citation><mixed-citation xml:lang="en">Tanabe A., Egashira Y., Fukuoka S. et al. Expression of rat hepatic 2-amino-3-carboxymuconate6-semialdehyde decarboxylase is affected by a high protein diet and by streptozotocin-induced diabetes. J Nutr. 2002. 132(6). 1153-9. DOI 10.1093/jn/132.6.1153.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sinclair L.V., Neyens D., Ramsay G. et al. Single cell analysis of kynurenine and System L amino acid transport in T cells. Nat. Commun. 2018. 9. DOI10.1038/s41467-018-04366-7.</mixed-citation><mixed-citation xml:lang="en">Sinclair L.V., Neyens D., Ramsay G. et al. Single cell analysis of kynurenine and System L amino acid transport in T cells. Nat. Commun. 2018. 9. DOI10.1038/s41467-018-04366-7.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Muzik O., Burghardt P., Yi Z. et al. Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway. Biochem. Biophys. Res. Commun. 2017. 488. 29-32. DOI10.1016/j.bbrc.2017.04.155.</mixed-citation><mixed-citation xml:lang="en">Muzik O., Burghardt P., Yi Z. et al. Successful metformin treatment of insulin resistance is associated with down-regulation of the kynurenine pathway. Biochem. Biophys. Res. Commun. 2017. 488. 29-32. DOI10.1016/j.bbrc.2017.04.155.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">O’Kell A.L., Wasserfall C., Guingab-Cagmat J. et al. Targeted metabolomic analysis identifies increased serum levels of GABA and branched chain amino acids in canine diabetes. Metabolomics. 2021. 17. 1-13. DOI 10.1007/s11306-021-01850-y.</mixed-citation><mixed-citation xml:lang="en">O’Kell A.L., Wasserfall C., Guingab-Cagmat J. et al. Targeted metabolomic analysis identifies increased serum levels of GABA and branched chain amino acids in canine diabetes. Metabolomics. 2021. 17. 1-13. DOI 10.1007/s11306-021-01850-y.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Oxenkrug G.F. Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. MolNeurobiol. 2015. 52(2). 805-810. DOI 10.1007/s12035-015-9232-0.</mixed-citation><mixed-citation xml:lang="en">Oxenkrug G.F. Increased Plasma Levels of Xanthurenic and Kynurenic Acids in Type 2 Diabetes. MolNeurobiol. 2015. 52(2). 805-810. DOI 10.1007/s12035-015-9232-0.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Munipally P.K., Agraharm S.G., Valavala V.K. et al. Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch. Physiol. Biochem. 2011. 117. 254-258. DOI10.3109/13813455.2011.623705.</mixed-citation><mixed-citation xml:lang="en">Munipally P.K., Agraharm S.G., Valavala V.K. et al. Evaluation of indoleamine 2,3-dioxygenase expression and kynurenine pathway metabolites levels in serum samples of diabetic retinopathy patients. Arch. Physiol. Biochem. 2011. 117. 254-258. DOI10.3109/13813455.2011.623705.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Debnath S., Velagapudi C., Redus L. et al. Tryptophan Metabolism in Patients with Chronic Kidney Disease Secondary to Type 2 Diabetes: Relationship to Inflammatory Markers. Int. J. Tryptophan Res. 2017. 10. 1178646917694600. DOI 10.1177/1178646917694600.</mixed-citation><mixed-citation xml:lang="en">Debnath S., Velagapudi C., Redus L. et al. Tryptophan Metabolism in Patients with Chronic Kidney Disease Secondary to Type 2 Diabetes: Relationship to Inflammatory Markers. Int. J. Tryptophan Res. 2017. 10. 1178646917694600. DOI 10.1177/1178646917694600.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Q., Ding Y., Song P. et al. Tryptophan-Derived 3-Hydroxyanthranilic Acid Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice In Vivo. Circulation. 2017. 136. 2271-83. DOI 10.1161/CIRCULATIONAHA.117.030972.</mixed-citation><mixed-citation xml:lang="en">Wang Q., Ding Y., Song P. et al. Tryptophan-Derived 3-Hydroxyanthranilic Acid Contributes to Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Mice In Vivo. Circulation. 2017. 136. 2271-83. DOI 10.1161/CIRCULATIONAHA.117.030972.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kotlinska-Hasiec E., Nowicka-Stazka P., Parada-Turska J. et al. Plasma Kynurenic Acid Concentration in Patients Undergoing Cardiac Surgery: Effect of Anaesthesia. Arch. Immunol. Ther. Exp.2015. 63. 129-137. DOI 10.1007/s00005-014-0312-z.</mixed-citation><mixed-citation xml:lang="en">Kotlinska-Hasiec E., Nowicka-Stazka P., Parada-Turska J. et al. Plasma Kynurenic Acid Concentration in Patients Undergoing Cardiac Surgery: Effect of Anaesthesia. Arch. Immunol. Ther. Exp.2015. 63. 129-137. DOI 10.1007/s00005-014-0312-z.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Liu J.J., Raynal S., Bailbe D. et al. Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity.Biochim. Biophys. Acta. 2015. 1852. 980-991. DOI10.1016/j.bbadis.2015.02.001.</mixed-citation><mixed-citation xml:lang="en">Liu J.J., Raynal S., Bailbe D. et al. Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity.Biochim. Biophys. Acta. 2015. 1852. 980-991. DOI10.1016/j.bbadis.2015.02.001.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Marszalek-Grabska M., Walczak K., Gawel K. et al. Kynurenine emerges from the shadows – Current knowledge on its fate and function. Pharmacol. Ther. 2021. 225. 107845. DOI 10.1016/j.pharmthera.2021.107845.</mixed-citation><mixed-citation xml:lang="en">Marszalek-Grabska M., Walczak K., Gawel K. et al. Kynurenine emerges from the shadows – Current knowledge on its fate and function. Pharmacol. Ther. 2021. 225. 107845. DOI 10.1016/j.pharmthera.2021.107845.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Yamamoto T., Hatabayashi K., Arita M, et al. Kynurenine signaling through the aryl hydrocarbon receptor maintains the undifferentiated state of human embryonic stem cells. Sci. Signal. 2019. 12. eaaw3306. DOI10.1126/scisignal.aaw3306.</mixed-citation><mixed-citation xml:lang="en">Yamamoto T., Hatabayashi K., Arita M, et al. Kynurenine signaling through the aryl hydrocarbon receptor maintains the undifferentiated state of human embryonic stem cells. Sci. Signal. 2019. 12. eaaw3306. DOI10.1126/scisignal.aaw3306.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Biljes D., Hammerschmidt-Kamper C., Kadow S. et al. Impaired glucose and lipid metabolism in ageing aryl hydrocarbon receptor deficient mice. EXCLI J. 2015. 14. 1153-1163. DOI10.17179/excli2015-638.</mixed-citation><mixed-citation xml:lang="en">Biljes D., Hammerschmidt-Kamper C., Kadow S. et al. Impaired glucose and lipid metabolism in ageing aryl hydrocarbon receptor deficient mice. EXCLI J. 2015. 14. 1153-1163. DOI10.17179/excli2015-638.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Dabir P., Marinic T.E., Krukovets I. et al. Aryl Hydrocarbon Receptor Is Activated by Glucose and Regulates the Thrombospondin-1 Gene Promoter in Endothelial Cells. Circ. Res. 2008. 102. 1558-1565. DOI10.1161/CIRCRESAHA.108.176990.</mixed-citation><mixed-citation xml:lang="en">Dabir P., Marinic T.E., Krukovets I. et al. Aryl Hydrocarbon Receptor Is Activated by Glucose and Regulates the Thrombospondin-1 Gene Promoter in Endothelial Cells. Circ. Res. 2008. 102. 1558-1565. DOI10.1161/CIRCRESAHA.108.176990.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Y., Liu H., McKenzie G. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med. 2010. 16. 279-285. DOI10.1038/nm.2092.</mixed-citation><mixed-citation xml:lang="en">Wang Y., Liu H., McKenzie G. et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat. Med. 2010. 16. 279-285. DOI10.1038/nm.2092.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Sakakibara K., Feng G.G., Li J. et al. Kynurenine causes vasodilation and hypotension induced by activation of KCNQ-encoded voltage-dependent K(+) channels. J. Pharmacol. Sci. 2015. 129. 31-37. DOI10.1016/j.jphs.2015.07.042.</mixed-citation><mixed-citation xml:lang="en">Sakakibara K., Feng G.G., Li J. et al. Kynurenine causes vasodilation and hypotension induced by activation of KCNQ-encoded voltage-dependent K(+) channels. J. Pharmacol. Sci. 2015. 129. 31-37. DOI10.1016/j.jphs.2015.07.042.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Ortega D.R., Muñiz P.E.U., Ayala T.B. et al. On the Antioxidant Properties of L-Kynurenine: An Efficient ROS Scavenger and Enhancer of Rat Brain Antioxidant Defense. Antioxidants. 2021. 11. 31. DOI 10.3390/antiox11010031.</mixed-citation><mixed-citation xml:lang="en">Ortega D.R., Muñiz P.E.U., Ayala T.B. et al. On the Antioxidant Properties of L-Kynurenine: An Efficient ROS Scavenger and Enhancer of Rat Brain Antioxidant Defense. Antioxidants. 2021. 11. 31. DOI 10.3390/antiox11010031.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Kaiser H., Parker E., Hamrick M.W. Kynurenine signaling through the aryl hydrocarbon receptor: Implications for aging and healthspan.Exp. Gerontol. 2020. 130. 110797. DOI 10.1016/j.exger.2019.110797.</mixed-citation><mixed-citation xml:lang="en">Kaiser H., Parker E., Hamrick M.W. Kynurenine signaling through the aryl hydrocarbon receptor: Implications 	for 	aging 	and 	healthspan.Exp. 	Gerontol. 	2020. 	130. 	110797. 	DOI 10.1016/j.exger.2019.110797.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zhen D., Liu J., Zhang X.D., Song Z. Kynurenic Acid Acts as a Signaling Molecule Regulating Energy Expenditure and Is Closely Associated With Metabolic Diseases. Front Endocrinol (Lausanne). 2022. 13. 847611. DOI 10.3389/fendo.2022.847611.</mixed-citation><mixed-citation xml:lang="en">Zhen D., Liu J., Zhang X.D., Song Z. Kynurenic Acid Acts as a Signaling Molecule Regulating Energy Expenditure and Is Closely Associated With Metabolic Diseases. Front Endocrinol (Lausanne). 2022. 13. 847611. DOI 10.3389/fendo.2022.847611.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Jung T.W., Park J., Sun J.L. et al. Administration of Kynurenic Acid Reduces HyperlipidemiaInduced Inflammation and Insulin Resistance in Skeletal Muscle and Adipocytes. Mol Cell Endocrinol. 2020. 518. 110928. DOI 10.1016/j.mce.2020.110928.</mixed-citation><mixed-citation xml:lang="en">Jung T.W., Park J., Sun J.L. et al. Administration of Kynurenic Acid Reduces HyperlipidemiaInduced Inflammation and Insulin Resistance in Skeletal Muscle and Adipocytes. Mol Cell Endocrinol. 2020. 518. 110928. DOI 10.1016/j.mce.2020.110928.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Agudelo L.Z., Ferreira D.M.S., Cervenka I. et al. Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and Inflammation. Cell Metab. 2018. 27(2). 378-392.e5. DOI10.1016/j.cmet.2018.01.004.</mixed-citation><mixed-citation xml:lang="en">Agudelo L.Z., Ferreira D.M.S., Cervenka I. et al. Kynurenic Acid and Gpr35 Regulate Adipose Tissue Energy Homeostasis and Inflammation. Cell Metab. 2018. 27(2). 378-392.e5. DOI10.1016/j.cmet.2018.01.004.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Pyun D.H., Kim T.J., Kim M.J. et al. Endogenous Metabolite, Kynurenic Acid, Attenuates Nonalcoholic Fatty Liver Disease viaAMPK/autophagy- and AMPK/ORP150-Mediated Signaling. J Cell Physiol. 2021. 236(7). 4902-12. DOI 10.1002/jcp.30199.</mixed-citation><mixed-citation xml:lang="en">Pyun D.H., Kim T.J., Kim M.J. et al. Endogenous Metabolite, Kynurenic Acid, Attenuates Nonalcoholic Fatty Liver Disease viaAMPK/autophagy- and AMPK/ORP150-Mediated Signaling. J Cell Physiol. 2021. 236(7). 4902-12. DOI 10.1002/jcp.30199.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Stone T.W., Stoy N., Darlington L.G. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci. 2013. 34(2). 136-43. DOI 10.1016/j.tips.2012.09.006.</mixed-citation><mixed-citation xml:lang="en">Stone T.W., Stoy N., Darlington L.G. An expanding range of targets for kynurenine metabolites of tryptophan. Trends Pharmacol Sci. 2013. 34(2). 136-43. DOI 10.1016/j.tips.2012.09.006.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Wang L., Cheng B., Ju Q., Sun B.K. AhR Regulates Peptidoglycan-Induced Inflammatory Gene Expression in Human Keratinocytes. J Innate Immun. 2022. 14(2). 124-134. DOI 10.1159/000517627.</mixed-citation><mixed-citation xml:lang="en">Wang L., Cheng B., Ju Q., Sun B.K. AhR Regulates Peptidoglycan-Induced Inflammatory Gene Expression in Human Keratinocytes. J Innate Immun. 2022. 14(2). 124-134. DOI 10.1159/000517627.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Cole J.E., Astola N., Cribbs A.P. et al. Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. Proc. Natl. Acad. Sci. USA. 2015. 112. 13033-13038. DOI 10.1073/pnas.1517820112.</mixed-citation><mixed-citation xml:lang="en">Cole J.E., Astola N., Cribbs A.P. et al. Indoleamine 2,3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development. Proc. Natl. Acad. Sci. USA. 2015. 112. 13033-13038. DOI 10.1073/pnas.1517820112.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Jamshed L., Debnath A., Jamshed S. et al. An Emerging Cross-Species Marker for Organismal Health: Tryptophan-Kynurenine Pathway. Int J Mol Sci. 2022. 23(11). 6300. DOI 10.3390/ijms23116300.</mixed-citation><mixed-citation xml:lang="en">Jamshed L., Debnath A., Jamshed S. et al. An Emerging Cross-Species Marker for Organismal Health: Tryptophan-Kynurenine Pathway. Int J Mol Sci. 2022. 23(11). 6300. DOI 10.3390/ijms23116300.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein L.E., Leopold M.C., Huang X. et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry. 2000. 39(24). 7266-75. DOI 10.1021/bi992997s.</mixed-citation><mixed-citation xml:lang="en">Goldstein L.E., Leopold M.C., Huang X. et al. 3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. Biochemistry. 2000. 39(24). 7266-75. DOI 10.1021/bi992997s.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Fazio F., Carrizzo A., Lionetto L. et al. Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension? Front Pharmacol. 2017. 8. 214. DOI 10.3389/fphar.2017.00214.</mixed-citation><mixed-citation xml:lang="en">Fazio F., Carrizzo A., Lionetto L. et al. Vasorelaxing Action of the Kynurenine Metabolite, Xanthurenic Acid: The Missing Link in Endotoxin-Induced Hypotension? Front Pharmacol. 2017. 8. 214. DOI 10.3389/fphar.2017.00214.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Kalaska B., Ciborowski M., Domaniewski T. et al. Serum metabolic fingerprinting after exposure of rats to QUINolinic acid. J. Pharm. Biomed. Anal. 2016. 131. 175-182. DOI10.1016/j.jpba.2016.08.024.</mixed-citation><mixed-citation xml:lang="en">Kalaska B., Ciborowski M., Domaniewski T. et al. Serum metabolic fingerprinting after exposure of rats to QUINolinic acid. J. Pharm. Biomed. Anal. 2016. 131. 175-182. DOI10.1016/j.jpba.2016.08.024.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Chen T., Zheng X., Ma X. et al. Tryptophan Predicts the Risk for Future Type 2 Diabetes. PLoSONE. 2016. 11. e0162192. DOI 10.1371/journal.pone.0162192.</mixed-citation><mixed-citation xml:lang="en">Chen T., Zheng X., Ma X. et al. Tryptophan Predicts the Risk for Future Type 2 Diabetes. PLoSONE. 2016. 11. e0162192. DOI 10.1371/journal.pone.0162192.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Литвинов Р.А., Гонтарева А.В., Усмиянова Л.Э., Клименко Д.Р. Влияние некоторых Dметаллов на образование конечных продуктов гликирования, агрегацию и амилоидную трансформацию альбумина в реакции гликирования. Фармация и фармакология. 2021. 9(4):306-317. DOI.10.19163/2307-9266-2021-9-4-306-317</mixed-citation><mixed-citation xml:lang="en">Litvinov R.A., Gontareva A.V., Usmiyanova L.E., Klimenko D.R. The effect of some D-metals on the formation of glycation end products, aggregation and amyloid transformation of albumin in glycation reactions. Farmatsiya i farmakologiya. 2021. 9(4):306-317. DOI.10.19163/23079266-2021-9-4-306-317</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
